関節炎モノクローナル抗体の世界市場レポート 2025年

関節炎モノクローナル抗体市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR7.7％で837億6,000万米ドルに成長します。予測期間の成長は、併用療法、適応拡大、患者の嗜好、ヘルスケア支出の増加に起因しています。予測期間の主な動向には、バイオシミラーとバイオベッター、標的療法、在宅ケア投与、リアルワールドエビデンス、コストとアクセスの考慮、ドラッグデリバリーの進歩などがあります。

関節炎の世界の有病率の上昇は、関節炎モノクローナル抗体市場の成長を著しく促進しています。Global RA Networkの報告によると、2021年には全世界で3億5,000万人以上が関節炎に罹患しており、最も一般的なタイプは変形性関節症で、痛風、線維筋痛症、関節リウマチがこれに続きます。例えば、2024年2月の関節炎オーストラリアからの報告では、関節炎に苦しむオーストラリア人の数は、2025年の411万人から2040年には539万人に増加すると予測されています。その結果、関節炎の罹患率の増加が関節炎モノクローナル抗体市場の成長を促進しています。

個別化医薬品の承認の増加は、関節炎モノクローナル抗体市場を将来的に押し上げると予想されています。個別化医薬品とは、遺伝的、バイオマーカー、表現型、心理社会的特徴に基づいて設計された、個々の患者に特化した治療薬のことで、患者が治療にどのように反応するかを予測するのに役立ちます。モノクローナル抗体（mAB）は、個別化医療のアプローチに沿った新世代の医薬品であり、患者の予後を改善し、ヘルスケアの効率を向上させることが期待されています。例えば、個別化医療の導入を提唱する米国の非営利団体である個別化医療連合（Personalized Medicine Coalition）の報告書では、2024年2月に新たに承認された26の個別化治療薬、既存の個別化医薬品の19の適応拡大、12の診断検査薬の17の注目すべき新規または適応拡大の重要性が指摘されています。そのため、個別化医療に対する承認の増加が関節炎モノクローナル抗体市場の成長を牽引しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界関節炎モノクローナル抗体PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の関節炎モノクローナル抗体市場：成長率分析
• 世界の関節炎モノクローナル抗体市場の実績：規模と成長, 2019-2024
• 世界の関節炎モノクローナル抗体市場の予測：規模と成長, 2024-2029, 2034F
• 世界関節炎モノクローナル抗体総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の関節炎モノクローナル抗体市場薬物による、実績と予測, 2019-2024, 2024-2029F, 2034F
• レミケード
• ヒュミラ
• エンブレル
• リツキサン
• オレンシア
• アクテムラ
• シンポニ
• シムジア
• レムシマ
• 世界の関節炎モノクローナル抗体市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 関節リウマチ
• 変形性関節症
• 乾癬性関節炎
• 強直性脊椎炎
• 線維筋痛症
• その他の用途
• 世界の関節炎モノクローナル抗体市場：最終用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 調査機関
• その他のエンドユーザー

第7章 地域別・国別分析

• 世界の関節炎モノクローナル抗体市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の関節炎モノクローナル抗体市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 関節炎モノクローナル抗体市場：競合情勢
• 関節炎モノクローナル抗体市場：企業プロファイル
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Amgen Inc.
• Genentech Inc.
• GlaxoSmithKline plc.
• AstraZeneca plc
• Mylan N.V.
• Bristol Myers Squibb
• Eli Lilly and Company
• Thermo Fisher Scientific Inc.
• Sanofi SA
• Novo Nordisk A/S
• Daiichi Sankyo Company Ltd.
• Seattle Genetics
• Teva Pharmaceutical Industries Ltd.
• Shanghai Junshi Biosciences Co. Ltd.
• GenScript Biotech Corporation

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 関節炎モノクローナル抗体市場2029：新たな機会を提供する国
• 関節炎モノクローナル抗体市場2029：新たな機会を提供するセグメント
• 関節炎モノクローナル抗体市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Arthritis monoclonal antibodies represent an advanced class of biological medications specifically utilized for treating rheumatoid arthritis and immune-mediated inflammatory conditions. These medications work by inhibiting interleukin-6, a key inflammatory protein, thereby alleviating joint pain, swelling, and other inflammation-related symptoms. Additionally, they play a role in reducing the body's defense mechanism to prevent rejection of newly transplanted organs.

The primary types of drugs in this category include Remicade, Humira, Enbrel, Rituxan, Orencia, Actemra, Simponi, Cimzia, and Remsima. Remicade, for instance, is prescribed for individuals with moderately to severely active Crohn's disease who haven't responded well to other treatments. These medications find application across various conditions such as rheumatoid arthritis, osteoarthritis, psoriatic arthritis, ankylosing spondylitis, fibromyalgia, among others. Their utilization spans multiple sectors including hospitals, research institutes, and other healthcare domains.

The arthritis monoclonal antibodies market research report is one of a series of new reports from The Business Research Company that provides arthritis monoclonal antibodies market statistics, including arthritis monoclonal antibodies industry global market size, regional shares, competitors with arthritis monoclonal antibodies market share, detailed arthritis monoclonal antibodies market segments, market trends and opportunities, and any further data you may need to thrive in the arthritis monoclonal antibodies industry. This arthritis monoclonal antibodies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The arthritis monoclonal antibodies market size has grown strongly in recent years. It will grow from $58.09 billion in 2024 to $62.29 billion in 2025 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to the rising prevalence of arthritis, increasing awareness of arthritis monoclonal antibodies, expanding the range of approved arthritis monoclonal antibodies, government support for research and development, and increased investment from pharmaceutical companies.

The arthritis monoclonal antibodies market size is expected to see strong growth in the next few years. It will grow to $83.76 billion in 2029 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to combination therapies, expanding indications, patient preference, and increased healthcare spending. Major trends in the forecast period include biosimilars and biobetters, targeted therapies, homecare administration, real-world evidence, cost and access considerations, and advancements in drug delivery.

The rising global prevalence of arthritis has significantly fueled the growth of the arthritis monoclonal antibody market. The Global RA Network reported that in 2021, more than 350 million people worldwide were affected by arthritis, with osteoarthritis being the most common type, followed by gout, fibromyalgia, and rheumatoid arthritis. For example, a report from Arthritis Australia in February 2024 projected that the number of Australians suffering from arthritis will rise from 4.11 million in 2025 to 5.39 million by 2040. Consequently, the increasing incidence of arthritis is propelling the growth of the arthritis monoclonal antibody market.

The increasing approvals for personalized medicines are anticipated to boost the arthritis monoclonal antibody market in the future. Personalized medicines are therapeutic products tailored specifically to individual patients, designed based on genetic, biomarker, phenotypic, or psychosocial characteristics that can help predict how a patient will respond to treatment. Monoclonal antibodies (mABs) represent a new generation of drugs that align with the personalized medicine approach, holding promise for enhancing patient outcomes and improving healthcare efficiency. For example, a report from the Personalized Medicine Coalition, a U.S.-based non-profit organization advocating for the adoption of personalized medicine, noted in February 2024 the significance of 26 newly approved personalized treatments, 19 expanded indications for existing personalized medicines, and 17 noteworthy new or expanded indications for 12 diagnostic testing products. Therefore, the rise in approvals for personalized medicines is driving growth in the arthritis monoclonal antibody market.

The evolution of therapeutic monoclonal antibody products stands as a pivotal force in advancing the arthritis monoclonal antibody market. These highly efficient, target-specific antibodies excel in treating arthritis, surpassing small molecules and peptides. The market's expansion is evident through the introduction of a multitude of monoclonal antibody drugs dedicated to arthritis treatment, signifying enhanced therapeutic options.

Leading players in the arthritis monoclonal antibody market are introducing cost-effective biosimilar versions like Hulio to ensure more accessible treatment options. Hulio, a biosimilar variant of AbbVie's Humira, a prominent rheumatoid arthritis drug, was launched by Biocon Biologics in July 2023. Priced at a 5% discount to Humira, which currently stands at $6,922 per carton, Hulio caters to conditions like rheumatoid arthritis and psoriatic arthritis, aiming to make treatment more affordable.

In May 2023, Abiogen Pharma Spa, an Italy-based pharmaceutical company, acquired EffRx Pharmaceuticals SA for $8.77 million. The acquisition of a majority stake in EffRx is consistent with Abiogen's growth strategy. It provides a springboard for their international expansion and affirms their dedication to improving osteoarticular and bone metabolism diseases. EffRx Pharmaceuticals SA is a Switzerland-based pharmaceutical company involved in treating various disorders, including arthritis.

Major companies operating in the arthritis monoclonal antibodies market include Johnson & Johnson, Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc., AbbVie Inc., Amgen Inc., Genentech Inc., GlaxoSmithKline plc., AstraZeneca plc, Bristol Myers Squibb, Eli Lilly and Company, Thermo Fisher Scientific Inc., Sanofi SA, Daiichi Sankyo Company Ltd., Seattle Genetics, Teva Pharmaceutical Industries Ltd., Shanghai Junshi Biosciences Co. Ltd., GenScript Biotech Corporation, Sigma-Aldrich Co. LLC, AbGenomics Corp., ADC Therapeutics SA, Agensys Inc., Alexion Pharmaceuticals Inc., ALMAC Group Ltd., Ambrx Inc., Astellas Pharma Inc., Celgene Corporation, Celldex Therapeutics Inc., Boehringer Ingelheim International GmbH, Celltrion Inc., HanAll Biopharma Co. Ltd., Merck & Co. Inc., Mitsubishi Tanabe Pharma Corporation, Regeneron Pharmaceuticals Inc., Samsung Bioepis Co. Ltd.

North America was the largest region in the arthritis monoclonal antibodies market in 2024. The regions covered in the arthritis monoclonal antibodies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the arthritis monoclonal antibodies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The arthritis monoclonal antibodies market consists of sales of infliximab, adalimumab, golimumab, and certolizumab. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Arthritis Monoclonal Antibodies Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on arthritis monoclonal antibodies market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for arthritis monoclonal antibodies ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The arthritis monoclonal antibodies market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug: Remicade; Humira; Enbrel; Rituxan; Orencia; Actemra; Simponi; Cimzia; Remsima
• 2) By Application: Rheumatoid Arthritis; Osteoarthritis; Psoriatic Arthritis; Ankylosing Spondylitis; Fibromyalgia; Other Applications
• 3) By End-Use: Hospitals; Research Institutes; Other End-Users
• Subsegments:
• Companies Mentioned: Johnson & Johnson; Hoffmann-La Roche Ltd.; Novartis AG; Pfizer Inc.; AbbVie Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Arthritis Monoclonal Antibodies Market Characteristics

3. Arthritis Monoclonal Antibodies Market Trends And Strategies

4. Arthritis Monoclonal Antibodies Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Arthritis Monoclonal Antibodies Growth Analysis And Strategic Analysis Framework

• 5.1. Global Arthritis Monoclonal Antibodies PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Arthritis Monoclonal Antibodies Market Growth Rate Analysis
• 5.4. Global Arthritis Monoclonal Antibodies Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Arthritis Monoclonal Antibodies Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Arthritis Monoclonal Antibodies Total Addressable Market (TAM)

6. Arthritis Monoclonal Antibodies Market Segmentation

• 6.1. Global Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Remicade
• Humira
• Enbrel
• Rituxan
• Orencia
• Actemra
• Simponi
• Cimzia
• Remsima
• 6.2. Global Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Rheumatoid Arthritis
• Osteoarthritis
• Psoriatic Arthritis
• Ankylosing Spondylitis
• Fibromyalgia
• Other Applications
• 6.3. Global Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Research Institutes
• Other End-Users

7. Arthritis Monoclonal Antibodies Market Regional And Country Analysis

• 7.1. Global Arthritis Monoclonal Antibodies Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Arthritis Monoclonal Antibodies Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Arthritis Monoclonal Antibodies Market

• 8.1. Asia-Pacific Arthritis Monoclonal Antibodies Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Arthritis Monoclonal Antibodies Market

• 9.1. China Arthritis Monoclonal Antibodies Market Overview
• 9.2. China Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Arthritis Monoclonal Antibodies Market

• 10.1. India Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Arthritis Monoclonal Antibodies Market

• 11.1. Japan Arthritis Monoclonal Antibodies Market Overview
• 11.2. Japan Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Arthritis Monoclonal Antibodies Market

• 12.1. Australia Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Arthritis Monoclonal Antibodies Market

• 13.1. Indonesia Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Arthritis Monoclonal Antibodies Market

• 14.1. South Korea Arthritis Monoclonal Antibodies Market Overview
• 14.2. South Korea Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Arthritis Monoclonal Antibodies Market

• 15.1. Western Europe Arthritis Monoclonal Antibodies Market Overview
• 15.2. Western Europe Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Arthritis Monoclonal Antibodies Market

• 16.1. UK Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Arthritis Monoclonal Antibodies Market

• 17.1. Germany Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Arthritis Monoclonal Antibodies Market

• 18.1. France Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Arthritis Monoclonal Antibodies Market

• 19.1. Italy Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Arthritis Monoclonal Antibodies Market

• 20.1. Spain Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Arthritis Monoclonal Antibodies Market

• 21.1. Eastern Europe Arthritis Monoclonal Antibodies Market Overview
• 21.2. Eastern Europe Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Arthritis Monoclonal Antibodies Market

• 22.1. Russia Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Arthritis Monoclonal Antibodies Market

• 23.1. North America Arthritis Monoclonal Antibodies Market Overview
• 23.2. North America Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Arthritis Monoclonal Antibodies Market

• 24.1. USA Arthritis Monoclonal Antibodies Market Overview
• 24.2. USA Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Arthritis Monoclonal Antibodies Market

• 25.1. Canada Arthritis Monoclonal Antibodies Market Overview
• 25.2. Canada Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Arthritis Monoclonal Antibodies Market

• 26.1. South America Arthritis Monoclonal Antibodies Market Overview
• 26.2. South America Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Arthritis Monoclonal Antibodies Market

• 27.1. Brazil Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Arthritis Monoclonal Antibodies Market

• 28.1. Middle East Arthritis Monoclonal Antibodies Market Overview
• 28.2. Middle East Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Arthritis Monoclonal Antibodies Market

• 29.1. Africa Arthritis Monoclonal Antibodies Market Overview
• 29.2. Africa Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Arthritis Monoclonal Antibodies Market Competitive Landscape And Company Profiles

• 30.1. Arthritis Monoclonal Antibodies Market Competitive Landscape
• 30.2. Arthritis Monoclonal Antibodies Market Company Profiles
  • 30.2.1. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Arthritis Monoclonal Antibodies Market Other Major And Innovative Companies

• 31.1. Amgen Inc.
• 31.2. Genentech Inc.
• 31.3. GlaxoSmithKline plc.
• 31.4. AstraZeneca plc
• 31.5. Mylan N.V.
• 31.6. Bristol Myers Squibb
• 31.7. Eli Lilly and Company
• 31.8. Thermo Fisher Scientific Inc.
• 31.9. Sanofi SA
• 31.10. Novo Nordisk A/S
• 31.11. Daiichi Sankyo Company Ltd.
• 31.12. Seattle Genetics
• 31.13. Teva Pharmaceutical Industries Ltd.
• 31.14. Shanghai Junshi Biosciences Co. Ltd.
• 31.15. GenScript Biotech Corporation

32. Global Arthritis Monoclonal Antibodies Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Arthritis Monoclonal Antibodies Market

34. Recent Developments In The Arthritis Monoclonal Antibodies Market

35. Arthritis Monoclonal Antibodies Market High Potential Countries, Segments and Strategies

• 35.1 Arthritis Monoclonal Antibodies Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Arthritis Monoclonal Antibodies Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Arthritis Monoclonal Antibodies Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer